Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Purdue OxyContin Abuse-Resistant Pill Will Need 4-5 Years To Complete Trials

  • News

Executive Summary

Purdue expects clinical trials of abuse-resistant OxyContin formulated with the opioid antagonist naltrexone will take four to five years to complete, after determining that a combination product with naloxone will likely not be feasible

You may also be interested in...



Subutex/Suboxone Prescriber Registration Efforts Ramping Up After Approval

The Substance Abuse & Mental Health Services Administration is working to register physicians to prescribe Schering-Plough/Reckitt Benckiser's opioid addiction treatment therapies Subutex and Suboxone in advance of the products' launch

Subutex/Suboxone Prescriber Registration Efforts Ramping Up After Approval

The Substance Abuse & Mental Health Services Administration is working to register physicians to prescribe Schering-Plough/Reckitt Benckiser's opioid addiction treatment therapies Subutex and Suboxone in advance of the products' launch

Purdue OxyContin Marketing Strategy To Be Topic Of GAO Investigation

Purdue Pharma's marketing strategies for OxyContin will be the topic of a Government Accounting Office report requested by House Appropriations/Commerce, Justice, State & Judiciary Subcommittee Chairman Frank Wolf (R-Va.)

Table

View full table

Tags:
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS040061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By